Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Material Litigation
confidence 92%
filed 2026-08-24
Item 8.01
This disclosure centers on a series of material court orders in multiple related pipeline litigation cases involving Sable Offshore Corp. The Company faces a $1.449 million penalty for violating a consent decree, declaratory judgments affecting its pipeline operations, and ongoing legal challenges to its restart of the Santa Ynez Pipeline System. These outcomes directly impact the Company's ability to operate its core business asset and represent material litigation developments that would affect a reasonable investor's assessment of the registrant's legal and operational risks.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-20
Item 8.01
Abbott announced settlement of material litigation involving specialty formulas for preterm infants, resolving the Gill case (which had a $495 million jury verdict in July 2024) and claims on behalf of approximately 2,000 other individuals for an aggregate settlement amount of approximately $670 million, with approximately 1,700 pending lawsuits involving approximately 12,700 individual infants remaining.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 85%
filed 2026-08-20
Vale discloses that 19 additional municipalities have joined a "Definitive Agreement for the compensation and reparation of damages arising from the collapse of the Fundão dam" in Mariana, Minas Gerais (which occurred November 5, 2015). This represents a material settlement of a major environmental and legal liability affecting 45 of 49 eligible municipalities. The agreement involves waiver of lawsuits and judicial proceedings in Brazil and abroad, with significant financial obligations (lump-sum payments plus installment schedules). This is a material litigation settlement that would affect a reasonable investor's assessment of Vale's contingent liabilities and legal exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-08-19
Item 8.01
The filing discloses material shareholder litigation challenging the Merger Agreement and proxy disclosures. Three complaints were filed on August 6 and August 17, 2026 (McDaniels, Clark, and Drulias) alleging materially false and misleading statements in the proxy statement and seeking injunctive relief to prevent the merger or damages. Additionally, Crinetics received multiple demand letters from shareholders requesting corrective disclosures. While the company denies the allegations, the disclosure of pending litigation that could enjoin a $10 billion merger transaction is material to investors evaluating the merger.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-19
Item 8.01
Aurinia announced a settlement agreement with Teva resolving patent infringement litigation over voclosporin generic entry. The settlement stipulates validity and enforceability of two key patents expiring in December 2037 and grants Aurinia market exclusivity until December 7, 2036. This is a material litigation settlement that directly affects the company's ability to protect its lead commercial product (LUPKYNIS/voclosporin) from generic competition, a core business asset for a biopharmaceutical company.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-17
Item 8.01
The filing discloses a derivative lawsuit filed on August 14, 2026, against GPHC and certain officers and directors, asserting claims for federal securities law violations, breach of fiduciary duty, aiding and abetting, waste of corporate assets, and unjust enrichment. This is material litigation that would affect a reasonable investor's assessment of the company's legal and financial exposure, particularly given the serious nature of the allegations and the involvement of current and former executives.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-17
Item 8.01
The filing discloses settlement of material litigation with Puritan Partners LLC that had been pending since November 2023 and "hindered our ability to raise capital and pursue strategic opportunities." The settlement involves exchange of existing debt instruments for new $2.35 million senior secured convertible notes maturing in February 2028. This is a material litigation settlement that removes a significant constraint on the company's operations and capital access, making it material to investors.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-08-17
Item 8.01
The disclosure announces the voluntary dismissal with prejudice of a lawsuit filed by James C. Justice, II and related parties against Carter Bankshares and Carter Bank & Trust in West Virginia state court. While the dismissal itself is favorable to the Company, the filing of material litigation by a significant party (Justice, a prominent West Virginia figure with substantial business interests) and its resolution is a material event that would affect a reasonable investor's assessment of the Company's legal and operational risks. The dismissal with prejudice is the resolution of previously disclosed litigation.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-08-14
Item 8.01
The Company and Carmell Regen settled litigation with Puritan, with parties agreeing to file a stipulation dismissing the case. The settlement is documented in a Settlement Agreement and involves material financial and operational consequences.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-08-10
Item 8.01
The filing discloses three stockholder lawsuits (Garfield, O'Connor, and Turner) challenging the Merger on grounds of materially false or misleading proxy disclosures, conflicts of interest, and deficient merger process disclosures. The Company also received demand letters alleging disclosure deficiencies. Although the Company denies merit and believes the allegations are without merit, it voluntarily supplemented proxy disclosures "solely to avoid the nuisance, risks, costs, and uncertainties inherent in disputes" and to prevent delay or adverse effects on the Merger. This is material litigation related to a pending M&A transaction that could affect shareholder voting and deal completion.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-08-10
The 6-K discloses a securities class action complaint filed on July 23, 2026, in New York Supreme Court naming Basel Medical Group Ltd and more than 30 other publicly traded companies as defendants, with service on the Company's process agent on August 5, 2026. This is a material litigation disclosure that would affect a reasonable investor's assessment of the Company's legal and financial exposure, even though the Company states it is unable to predict the outcome at this early stage.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-10
Item 8.01
This disclosure reports the preliminary court approval of a settlement of consolidated stockholder derivative litigation against Evolv's board and management, resolving claims arising from improper sales practices, revenue recognition errors, and false marketing claims regarding the company's core technology. The settlement includes mandatory corporate governance reforms and was preceded by FTC and SEC investigations, an accounting restatement, and delayed financial results—all material events that affected investor confidence. Although no monetary payment is required from the company, the settlement's approval by the federal court and the binding governance reforms constitute a material resolution of significant litigation that directly addresses the company's past disclosure and internal control failures.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-07
Item 8.01
This disclosure reports settlement of material shareholder litigation challenging Illumina's $8 billion GRAIL acquisition. The settlement involves mutual releases and dismissal with prejudice as to the named plaintiffs (Icahn Partners LP, et al.) in Delaware Court of Chancery case C.A. No. 2023-1045-PAF, pending court approval at a November 2, 2026 hearing. The underlying claims alleged breach of fiduciary duties related to the GRAIL transaction, regulatory scrutiny, and inadequate disclosures in 2023 proxy filings—matters material to investors assessing the company's governance and acquisition decision-making.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-07
Item 8.01
The filing discloses preliminary court approval of a settlement of consolidated shareholder derivative lawsuits against CorMedix and its officers/directors. The underlying claims allege breach of fiduciary duties related to false/misleading statements about manufacturing deficiencies that delayed FDA approval of DefenCath, resulting in a securities fraud class action and significant harm to the company. The settlement requires implementation of corporate governance reforms over 3.5 years, with potential attorneys' fees up to $3.9 million. This is a material litigation settlement with substantial corporate governance consequences.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-08-06
Item 1.01
iRhythm Technologies and Baxter settled patent litigation involving mutual accusations of patent infringement with a $50 million settlement payment and cross-licenses, resolving all outstanding patent disputes and including covenants not to sue for six years.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 75%
filed 2026-08-05
Item 7.01
The disclosure describes an active investigation by the FDA and Minnesota Department of Health into a salmonella outbreak affecting Chipotle's supply chain across multiple states. While framed as a health and safety matter, this constitutes a material regulatory investigation that could result in enforcement action, liability, or reputational harm. The company's proactive ingredient removal and cooperation with authorities, combined with the explicit statement that guidance did not include financial impacts due to "uncertain nature of any possible outcomes," signals material regulatory risk requiring investor disclosure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-05
Item 8.01
This disclosure reports the final resolution of a material arbitration dispute initiated by NorthStar Earth & Space against Legacy Spire, with the arbitral tribunal issuing a Final Award of approximately $12.4 million in favor of Spire Global on July 31, 2026. The tribunal dismissed all of NorthStar's claims (including fraud allegations) and granted Legacy Spire's counterclaims for the promissory note, injunction costs, and arbitration costs. This material litigation settlement outcome would significantly affect a reasonable investor's assessment of the company's legal exposure and financial position.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-08-05
On August 3, 2026, XTL Biopharmaceuticals was served with a shareholder derivative motion in Israeli court alleging that the controlling shareholder and current/former directors breached fiduciary duties in connection with the 2024 acquisition of The Social Proxy Ltd., including alleged failures to fund the subsidiary, conflicts of interest, delayed disclosure, and financial irregularities. The petitioner seeks court authorization to file a derivative claim, monetary compensation estimated at approximately NIS 100 million, disgorgement, forensic accounting, and attorneys' fees. This is a material litigation disclosure involving substantial alleged damages and governance failures.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-04
Item 8.01
The Company filed a lawsuit in Delaware Court of Chancery against Kuva Labs and its subsidiary alleging breach of a Merger Agreement dated March 6, 2026, and seeking damages for stockholder benefits.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-08-04
The 6-K discloses material litigation commenced by J.B.D Innovation Ltd. and Victor Tshuva & Co. in the Haifa District Court on August 2, 2026, challenging the Company's private placement of 1,000,000 ordinary shares and warrants. The Court issued an interim ex parte order temporarily prohibiting the Company from advancing the Private Placement or effecting changes to its capital structure, with a hearing scheduled for August 12, 2026. This litigation directly blocks a material capital-raising transaction and creates substantial uncertainty regarding the Company's ability to complete the Private Placement, making it material to investors.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-08-04
The filing discloses settlement of litigation commenced by former CFO Doug Durst in connection with his employment termination. The Company paid $247,500 in cash to Durst and $55,890 to his affiliate Chase Innovations, plus issued a warrant for 57,600 shares at $4.11 exercise price. This represents a material settlement of an employment-related dispute that would affect investor assessment of the registrant's legal and financial position.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-08-03
EX-99.10
TotalEnergies announced its decision to appeal a June 25, 2026 judgment rendered by the Paris Judicial Court in a duty of vigilance climate case brought by certain associations under French law, representing a material legal development affecting the company's regulatory and legal exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-03
Item 8.01
Teads filed a lawsuit against Google LLC and Alphabet Inc. in the U.S. District Court for the Southern District of New York on August 3, 2026, alleging unlawful anticompetitive practices in digital advertising technology markets, including monopolization, illegal tying, and deceptive practices spanning over a decade. The complaint asserts seven counts under Sherman Act and state law, seeking financial damages and other remedies.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-07-31
Item 8.01
The Seoul Central District Court issued a judgment against Franklin Technology Inc. (a subsidiary of Franklin Wireless Corp.) ordering payment of approximately $3.67 million in damages plus interest in a commercial contract dispute with Partron Co., Ltd. This is a material litigation settlement/judgment that would affect a reasonable investor's assessment of the company's financial obligations and legal exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-07-30
The filing discloses preliminary court approval of a settlement of consolidated stockholder derivative litigation (In re Latch Inc. Derivative Litigation, Case No. 1:23-cv-01273-JGK) alleging breaches of fiduciary duties and false statements regarding financial metrics. The settlement includes a $450,000 fee and expense payment to plaintiffs' counsel and comprehensive corporate governance reforms to be implemented for 3.5 years. This is a material litigation settlement that would affect a reasonable investor's assessment of the company's governance and legal exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-07-30
Item 7.01
AnaptysBio disclosed material litigation against Tesaro and GlaxoSmithKline regarding alleged material breach of a Collaboration and Exclusive License Agreement and tortious interference. The filing provides substantive updates on trial completion (July 14-17, 2026) and a court-approved post-trial briefing schedule, indicating this is an ongoing material dispute with significant financial and operational implications for the Company's collaboration arrangements.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-07-29
Item 8.01
The filing discloses a material litigation development: dismissal of two major antitrust lawsuits against Westlake in the Netherlands and Germany, including one by Shell Chemical Europe alleging approximately €1,025 million in damages. Although the dismissals are favorable to the Company, they remain subject to appeal and twelve related lawsuits are still pending, making this a significant material litigation event affecting investor assessment of the Company's legal exposure and contingent liabilities.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-07-29
The 6-K discloses settlement of a material lawsuit filed by shareholders against the Company and Co-CEO Satoshi Kobayashi in Tokyo District Court in December 2023. The Plaintiffs originally sought USD 2.925 million in damages for alleged breach of obligation related to the IPO. On July 17, 2026, a judicial settlement was reached with a settlement payment of JPY 20 million (approximately USD 122,000) completed on July 27, 2026, and withdrawal of provisional attachments on the Company's bank accounts. This settlement of material litigation affecting a named executive and the Company's operations is material to investors.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-07-28
Item 7.01
Judge Denise Cote of the U.S. District Court for the Southern District of New York entered an Opinion and Order awarding $719 million in disgorgement of unjust profits plus attorney's fees and costs to Skillz Platform Inc. (Firy's subsidiary) in a false advertising lawsuit against Papaya Gaming under the Lanham Act and New York General Business Law. This is a material litigation settlement/judgment that materially affects the registrant's financial position and would significantly influence a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-07-27
Item 7.01
Johnson & Johnson announced a comprehensive settlement agreement for ovarian talc litigation with a $5.5 billion commitment, resolving approximately 76,000 remaining claims. This represents a material settlement of long-standing product liability litigation that would significantly affect investor assessment of the company's financial obligations and legal exposure. The settlement follows a favorable MDL court ruling on causation but constitutes a major resolution of a 15-year litigation matter.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-07-27
Item 8.01
The Company disclosed an adverse arbitration decision rendered on July 24, 2026, dismissing its claims against 3D Medicines and imposing approximately $1.0 million in legal fees and costs on the Company. This outcome materially affects the Company's financial position and its rights under the exclusive license agreement for galinpepimut-S, with $191.5 million in potential future milestone payments at stake.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-27
Item 8.01
Vulcan disclosed a NAFTA tribunal decision in a long-standing arbitration against Mexico over alleged violations related to the company's aggregates reserves and quarrying operations. Although the tribunal found Mexico violated NAFTA, the monetary damages award was "negligible." This is a material litigation/arbitration outcome affecting a significant international business dispute that has been pending since 2018, warranting disclosure under Item 8.01 (Other Events) as a material legal matter.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-24
Item 8.01
The filing discloses two stockholder lawsuits filed in New York Supreme Court (O'Toole v. GBTG and Lawrence v. GBTG) alleging omissions and misstatements in the Definitive Proxy Statement related to the pending merger. The complaints seek injunctions against the stockholder vote and merger consummation, rescission, and damages. Although the company denies liability and voluntarily supplemented disclosures to moot claims, the existence of active litigation seeking to enjoin a material transaction qualifies as material litigation under Item 8.01.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-07-24
Item 7.01
A jury issued an advisory verdict awarding $604 million in compensatory damages against C.H. Robinson in a trucking accident lawsuit. This is a material litigation event involving a substantial financial exposure that would affect a reasonable investor's assessment of the company's financial condition and contingent liabilities, even though the verdict remains subject to post-trial proceedings and appeal.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-07-22
The 6-K discloses two material litigation matters: (1) a shareholder derivative discovery motion filed July 16, 2026 by Gad Libman seeking court-ordered inspection of company documents related to recent public disclosures, with a hearing scheduled for December 15, 2026; and (2) a class action certification motion filed July 21, 2026 by Hadar Shamai alleging misleading statements regarding the residential proxy business, claiming damages up to NIS 120 million and seeking certification on behalf of shareholders who purchased between March 29, 2022 and July 2, 2026. Both matters involve allegations of securities law violations and would materially affect a reasonable investor's assessment of the registrant's legal and financial exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-07-22
Item 1.01
The Company settled material litigation filed by the Jeffrey L. Feinberg Personal Trust against ONAR LLC alleging breach of contract and unjust enrichment on a $1.5 million Senior Secured Promissory Note. Under the settlement agreement executed July 16, 2026, the Company is obligated to pay $1.5 million principal plus 18% annual interest through February 2030, with dismissal and mutual release of claims.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-21
Item 8.01
The filing discloses three stockholder complaints filed against Corebridge and/or Equitable (Johnson, Clark, and Lacoff complaints) challenging the adequacy of disclosures in the merger proxy statement and seeking injunctions against the stockholder vote, rescission of the Mergers, and corrective disclosures. Additionally, demand letters from purported stockholders have been received. While the company denies merit and characterizes these as nuisance claims, the disclosure of multiple active lawsuits seeking to enjoin a material transaction qualifies as material litigation under Item 8.01.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-21
Item 8.01
The filing discloses three stockholder complaints (Johnson, Clark, and Lacoff) filed against Corebridge and its board challenging disclosures in the merger proxy statement, plus demand letters from purported stockholders. While the primary Item 8.01 context is the merger transaction, the salient disclosed event is the material litigation—specifically, stockholder derivative/class action complaints seeking injunctions against the stockholder vote, rescission of the Mergers, corrective disclosures, and attorneys' fees. The company is voluntarily supplementing disclosures to moot these allegations, indicating the litigation is material to investors evaluating the merger.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-07-21
Item 8.01
The disclosure reports the final resolution of a material litigation between Miami International Holdings and Nasdaq that spanned nearly nine years (September 2017 to July 2026). The Order of Dismissal With Prejudice resolves all claims and counterclaims, and critically grants the Company unrestricted freedom to operate its exchanges, trading platforms, and technology without license or consent from Nasdaq or risk of infringement claims. This settlement removes significant operational and legal constraints that had been asserted by Nasdaq, making it material to investors' assessment of the Company's business prospects and competitive position.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-07-20
Item 8.01
NeoGenomics settled a Department of Justice/Office of Inspector General investigation concerning consulting services provided under its Laboratory Collaboration Initiative program, agreeing to pay $9,813,260 plus interest. The settlement resolves a matter the company self-disclosed in November 2021 and for which it had previously accrued $11.2 million in reserves, materially affecting the company's regulatory compliance and financial position.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-20
Item 7.01
The filing discloses settlement of legal disputes involving Trump Media, Patrick Orlando, and ARC Global Investments II LLC pursuant to a confidential settlement agreement. While the specific claims and settlement terms are not detailed, the announcement of resolution of multiple legal disputes among named parties constitutes a material litigation settlement event that would affect investor assessment of the company's legal and financial position.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-07-17
Item 8.01
The filing discloses material litigation filed on July 6, 2026, in New Jersey Superior Court challenging the Merger on grounds of materially incomplete and misleading proxy disclosures. The plaintiff seeks injunctive relief to enjoin the stockholder vote scheduled for July 23, 2026, and a motion for preliminary injunction was filed on July 13, 2026. This litigation directly threatens the timing and completion of a material M&A transaction and would affect a reasonable investor's assessment of deal risk.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-07-17
Item 1.01
EyePoint settled potential False Claims Act and related civil violations with the DOJ, OIG-HHS, and DHA involving alleged improper sales and marketing practices for DEXYCU® from 2019–2023. The settlement requires payment of $4.68 million plus interest and attorneys' fees, and imposes a five-year Corporate Integrity Agreement with significant compliance obligations. This is a material government settlement resolving regulatory and civil liability exposure.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-07-17
The 6-K discloses settlement of material litigation: Helena Global Investment Opportunities I Ltd. filed a complaint in New York Supreme Court arising from a July 2025 purchase agreement. Sagtec settled on March 20, 2026, agreeing to pay $250,000 in two tranches, with the action discontinued on April 13, 2026. The settlement amount and formal resolution of a contractual dispute constitute a material litigation event requiring disclosure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 75%
filed 2026-07-16
Item 8.01
Arbutus and Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech seeking monetary relief and injunctions against their mRNA-LNP COVID-19 vaccines, asserting Arbutus's LNP patent portfolio.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-07-16
EX-99.1
Brazil Potash discloses a procedural filing by the Brazilian Federal Public Defender's Office seeking to suspend provisional relief and overturn favorable court decisions regarding the Autazes Project. Although characterized as a procedural development within existing litigation rather than a new lawsuit, the filing directly threatens the Company's ability to continue installation activities on its flagship project and represents a material legal challenge that would affect a reasonable investor's assessment of project viability and timeline. The Company's detailed response and emphasis on its favorable judicial record underscore the materiality of this litigation development.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-16
Item 1.01
VPR Brands disclosed settlement of a patent infringement litigation (R.J. Reynolds Vapor Company v. VPR Brands, LP, Case No. 1:26-cv-00459) involving a $14.9 million payment and grant of a perpetual, worldwide patent license. While the filing is technically under Item 1.01 (Material Definitive Agreement), the core event is resolution of material litigation through a settlement agreement, which is the salient disclosure for investor purposes.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 78%
filed 2026-07-16
Item 1.01
Sadot Group Inc. settled a material lawsuit (Helena Global Investment Opportunities I Ltd. v. Sadot Group Inc., Case No. 1:26-cv-05818) involving alleged breaches of financing agreements and claims for liquidated damages. Under the Settlement Agreement, the Company agreed to pay $350,000 in cash and terminate its $10,000,000 equity line of credit facility with Helena.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-07-15
The 6-K announces the final award in an arbitration proceeding against Juventas Co., Ltd. before the Hong Kong International Arbitration Centre. The tribunal rejected all of Juventas's breach allegations, determined Juventas wrongfully terminated the parties' agreements regarding CNCT-19 commercialization, and awarded CASI "well over RMB 100 million" in wasted costs, interest, tribunal costs, and legal fees. This is a material litigation settlement/award that would affect a reasonable investor's assessment of the company's financial position and legal standing.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 90%
filed 2026-07-14
Item 1.01
Bion Environmental Technologies settled material litigation with Hamstra Builders, Inc. related to construction of the Fair Oaks facility, with mechanics liens and litigation that commenced in April 2025. The settlement involves issuance of a $1.77M convertible note and extension of existing debt maturities, which the CEO characterized as among the company's largest challenges.
View raw filing on EDGAR →